Traduction de «al selected major risk » (Néerlandais → Français) :

Referenties : (1) EZZATI M, LOPEZ A, RODGERS A et al. Selected major risk factors and global and regional burden of disease.
Références : (1) EZZATI M, LOPEZ A, RODGERS A et al. Selected major risk factors and global and regional burden of

Sites : www.wwvh.be en www.ssmg.be (nog te verschijnen) (2) EZZATI M, LOPEZ A, RODGERS A et al. Selected major risk factors and global and regional burden of disease.
Sites : www.wwvh.be et www.ssmg.be (à paraître) (2) EZZATI M, LOPEZ A, RODGERS A et al. Selected major risk factors and global and regional burden of disease.

Q2 2010 selected major approvals: US, Europe and Japan Product Active ingredient Indication Approval date Certican Everolimus Kidney transplantation US – April Diovan Valsartan Pediatric hypertension EU – April Tasigna Nilotinib Newly diagnosed CML US – June
Autorisations importantes au deuxième trimestre 2010, USA, Europe et Japon Produit Substance active Indication Date d’autorisation Certican Evérolimus Transplantation rénale USA, avril Diovan Valsartan Hypertension pédiatrique UE, avril Tasigna Nilotinib LMC diagnostiquée précocement USA, juin

Q3 2010 selected major approvals: US, Europe and Japan Product Active ingredient Indication Approval date Gilenya fingolimod Multiple sclerosis US – September Tekamlo aliskiren,amlodipine Hypertension US - August
Autorisations importantes au troisième trimestre 2010: USA, Europe et Japon Produit Substance active Indication Date d’autorisation Gilenya fingolimod Sclérose en plaques USA, septembre Tekamlo aliskirène, amlodipine Hypertension USA, août

2010 selected major approvals: US, Europe and Japan Product Active ingredient Indication Approval date Afinitor Everolimus Kidney cancer Japan – Q1 Equa (Galvus) Vildagliptin Type 2 diabetes Japan – Q1 Exforge Valsartan and amlodipine Hypertension Japan – Q1
Autorisations importantes en 2010 Aux Etats-Unis, en Europe et au Japon Produit Substance active Indication Date d’autorisation Afinitor Evérolimus Cancer du rein Japon – T1 Equa (Galvus) Vildagliptine Diabète de type 2 Japon – T1 Exforge valsartan et amlodipine Hypertension Japon – T1

2 Het betreft volgende velden: PP0010, Major_risk_cat Flag, Minor_risk_cat flag, Major_coverage_yn Flag.
2 Il s’agit des champs suivants: PP0010, Major_risk_cat Flag, Minor_risk_cat flag, Major_coverage_yn Flag.

We are already able to say following the first debriefing that a number of major points were identified within the FAMHP, for instance, our approach to risk management or risk analysis.
We are already able to say following the first debriefing that a number of major points were identified within the FAMHP, for instance, our approach to risk management or risk analysis.

AGO178 (agomelatine), a once-daily investigational treatment for patients with major depression, will be studied in additional Phase III trials to further explore the benefit/risk and pharmacokinetic profile of this compound.
AGO178 (agomélatine), un traitement investigationnel par prise unique quotidienne contre la dépression sévère, fera l’objet d’une étude dans le cadre d’essais supplémentaires de phase III afin d’explorer plus avant le profil bénéfice/risque et pharmacocinétique de cette molécule.

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic.
Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic.

Diovan is the only medicine in the ARB class approved to treat the three major cardiovascular indications: high blood pressure, high-risk heart attack and heart failure.
Diovan est le seul médicament de la classe des ARA autorisé pour le traitement de trois indications cardiovasculaires majeures: hypertension, infarctus du myocarde à haut risque et insuffisance cardiaque.